ABBV
Stock Details
ABBV is AbbVie Inc.'s stock. Stock exchange NYSE (Currency USD). Average price in 50 days is 149.74$. Average daily volumn in 3 months 7.28M. Market cap 272.38B
Stock symbol : ABBV. Exchange : NYSE. Currency : USD Lastest price : 154.14$. Total volume : 599.74k. Market state REGULAR Click reload if you want to check the lastest price on market!!!
AbbVie Inc. (ABBV)
Last Price
154.14$Change
0.21Volume
599.74k
| Previous Close | 153.93 |
| Open | 154.61 |
| Day Range | 153.76-154.96 |
| Bid | 154.15 x 900 |
| Ask | 154.23 x 900 |
| Volume | 599.74k |
| Average Volume | 7.28M |
| Market Cap | 272.38B |
| Beta | 0.81 |
| 52 Week Range | 105.56-175.91 |
| Trailing P/E | 22.11 |
| Foward P/E | 12.89 |
| Dividend (Yield %) | 3.67% |
| Ex-Dividend Date | 2022-07-14 |
Financial Details
Organization
AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCL... EXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Market Cap:
272.38BRevenue:
56.2BTotal Assets:
146.53BTotal Cash:
9.75B
News about "AbbVie Inc."
AbbVie Inc. (NYSE:ABBV) Shares Sold by Waddell & Associates LLC
Source from : Defense World - 1 days ago
Waddell & Associates LLC cut its stake in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 23.2% in the first quarter, according to the company in its most recent disclosure with the SEC. The ...See details»
apricus wealth LLC Reduces Stock Holdings in AbbVie Inc. (NYSE:ABBV)
Source from : Defense World - 1 days ago
LLC reduced its position in shares of AbbVie Inc. (NYSE:ABBV – Get Rating) by 8.5% during the 1st quarter, according to the company in its most recent 13F filing with the Securities & Exchange ...See details»
This Blockbuster Drug from AbbVie Is Closer to Another Major Indication
Source from : Nasdaq - 1 days ago
The European Medicine Agency's Committee for Medicinal Products for Human Use (CHMP) recently adopted a positive opinion that recommended the approval of AbbVie's (NYSE: ABBV) Rinvoq for what would be ...See details»
Should You Consider Acquiring AbbVie (ABBV) Shares?
Source from : Yahoo! Sports - 2 days ago
Carillon Tower Advisers, an investment management firm, published its “Carillon Clarivest Capital Appreciation Fund” first quarter 2022 investor letter – a copy of which can be downloaded here. At the ...See details»
When Abbvie Inc (ABBV) Moves Investors should Listen
Source from : news.stocktradersdaily - 3 days ago
When Abbvie Inc ABBV Moves Investors should Listen ...See details»
AbbVie Inc. (ABBV) Outlook: Revisiting The Past For Future Insights
Source from : stocksregister - 6 days ago
AbbVie Inc. (NYSE:ABBV) at last check was buoying at $152.49 on Thursday, June 30, with a fall of -1.07% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»
Inspirion Wealth Advisors LLC Acquires 14,917 Shares of AbbVie Inc. (NYSE:ABBV)
Source from : ETF Daily News - 9 days ago
Inspirion Wealth Advisors LLC raised its holdings in AbbVie Inc. (NYSE:ABBV – Get Rating) by 6.4% during the first quarter, according to the company in its most recent filing with the Securities & ...See details»
Ritholtz Wealth Management Grows Stake in AbbVie Inc. (NYSE:ABBV)
Source from : ETF Daily News - 9 days ago
Ritholtz Wealth Management increased its position in AbbVie Inc. (NYSE:ABBV – Get Rating) by 279.3% in the first quarter, according to the company in its most recent filing with the Securities & ...See details»
AbbVie's (ABBV) Rinvoq Gets CHMP Nod for New Indication
Source from : Nasdaq - 9 days ago
ABBV announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (“CHMP”) has rendered a positive opinion on, and recommended granting approval to its JAK inhibitor ...See details»
AbbVie Inc. (ABBV) is Attracting Investor Attention: Here is What You Should Know
Source from : Yahoo Finance - 20 days ago
AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term.See details»
U.S. Intrauterine Devices Market worth USD 3 billion by 2030, says Global Market Insights Inc.
Source from : TMCnet - 1 days ago
U.S. intrauterine devices market value is projected to reach USD 3 billion by 2030, according to a new research report by Global Market Insights Inc. Favorable regulatory scenario along with rising ...See details»
AbbVie Rallies After Its Test of the Rising 200-Day Moving Average Line
Source from : TheStreet.com - 9 days ago
In this daily bar chart of , below, we can see that prices rallied back above the 50-day moving average line after touching/testing the rising 200-day line earlier this month. The ...See details»
AbbVie Declares Quarterly Dividend
Source from : Associated Press - 13 days ago
The board of directors of AbbVie Inc. (NYSE: ABBV) today declared a quarterly cash dividend of $1.41 per share. The cash dividend is payable August 15, 2022, to stockholders of record at the close of ...See details»
AbbVie Stock’s Healthy Yield Makes it a High-Conviction Holding
Source from : YAHOO!Finance - 9 days ago
Headquartered in Illinois, AbbVie (NYSE:ABBV) is a well-respected pharmaceutical businesses with a broad range of medical treatments and solutions. If you’re going to pick a pharmaceutical-market ...See details»